295 related articles for article (PubMed ID: 11819030)
1. Discrimination in 5-HT(3) receptor binding in murine brain and cultured cell preparations.
Zhang ZJ; Trivedi BL; de Paulis T; Schmidt DE; Hewlett WA
Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):123-32. PubMed ID: 11819030
[TBL] [Abstract][Full Text] [Related]
2. Decreased agonist, but not antagonist, binding to the naturally occurring Thr92Lys variant of the h5-HT7(a) receptor.
Brüss M; Kiel S; Bönisch H; Kostanian A; Göthert M
Neurochem Int; 2005 Aug; 47(3):196-203. PubMed ID: 15896881
[TBL] [Abstract][Full Text] [Related]
3. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
Cappelli A; Anzini M; Vomero S; Canullo L; Mennuni L; Makovec F; Doucet E; Hamon M; Menziani MC; De Benedetti PG; Bruni G; Romeo MR; Giorgi G; Donati A
J Med Chem; 1999 May; 42(9):1556-75. PubMed ID: 10229626
[TBL] [Abstract][Full Text] [Related]
4. Characterization of (S)-des-4-amino-3-[125I]iodozacopride ([125I]DAIZAC), a selective high-affinity radioligand for 5-hydroxytryptamine3 receptors.
Hewlett WA; Trivedi BL; Zhang ZJ; de Paulis T; Schmidt DE; Lovinger DM; Ansari MS; Ebert MH
J Pharmacol Exp Ther; 1999 Jan; 288(1):221-31. PubMed ID: 9862774
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
[TBL] [Abstract][Full Text] [Related]
6. 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with selective affinity for the 5-HT(4) receptor: synthesis and structure-affinity and structure-activity relationships of a new series of partial agonist and antagonist derivatives.
Tapia I; Alonso-Cires L; López-Tudanca PL; Mosquera R; Labeaga L; Innerárity A; Orjales A
J Med Chem; 1999 Jul; 42(15):2870-80. PubMed ID: 10425096
[TBL] [Abstract][Full Text] [Related]
7. Identification of serotonin 5-HT3 recognition sites in membranes of N1E-115 neuroblastoma cells by radioligand binding.
Hoyer D; Neijt HC
Mol Pharmacol; 1988 Mar; 33(3):303-9. PubMed ID: 3352595
[TBL] [Abstract][Full Text] [Related]
8. Serotonergic antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the rat 5-hydroxytryptamine type 2C receptor in Sf9 cells.
Labrecque J; Fargin A; Bouvier M; Chidiac P; Dennis M
Mol Pharmacol; 1995 Jul; 48(1):150-9. PubMed ID: 7623769
[TBL] [Abstract][Full Text] [Related]
9. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives.
Cappelli A; Anzini M; Vomero S; Mennuni L; Makovec F; Doucet E; Hamon M; Bruni G; Romeo MR; Menziani MC; De Benedetti PG; Langer T
J Med Chem; 1998 Feb; 41(5):728-41. PubMed ID: 9513601
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.
Chambers JJ; Parrish JC; Jensen NH; Kurrasch-Orbaugh DM; Marona-Lewicka D; Nichols DE
J Med Chem; 2003 Jul; 46(16):3526-35. PubMed ID: 12877591
[TBL] [Abstract][Full Text] [Related]
11. Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents.
Leopoldo M; Berardi F; Colabufo NA; Contino M; Lacivita E; Niso M; Perrone R; Tortorella V
J Med Chem; 2004 Dec; 47(26):6616-24. PubMed ID: 15588097
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of [3H]5-hydroxytryptamine binding to iris-ciliary body tissue of the rabbit.
Chidlow G; De Santis LM; Sharif NA; Osborne NN
Invest Ophthalmol Vis Sci; 1995 Oct; 36(11):2238-45. PubMed ID: 7558717
[TBL] [Abstract][Full Text] [Related]
13. Development of a scintillation proximity assay binding method for the human 5-hydroxytryptamine 6 receptor using intact cells.
Carrick T; Kowal D; Nawoschik S; Zhang G; Chan K; Dunlop J
Anal Biochem; 2008 Oct; 381(1):27-32. PubMed ID: 18601889
[TBL] [Abstract][Full Text] [Related]
14. [3H]RS-23597-190, a potent 5-hydroxytryptamine4 antagonist labels sigma-1 but not sigma-2 binding sites in guinea pig brain.
Bonhaus DW; Loury DN; Jakeman LB; Hsu SA; To ZP; Leung E; Zeitung KD; Eglen RM; Wong EH
J Pharmacol Exp Ther; 1994 Oct; 271(1):484-93. PubMed ID: 7965749
[TBL] [Abstract][Full Text] [Related]
15. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling.
Hirst WD; Abrahamsen B; Blaney FE; Calver AR; Aloj L; Price GW; Medhurst AD
Mol Pharmacol; 2003 Dec; 64(6):1295-308. PubMed ID: 14645659
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of 5-HT3 binding sites in NG108-15, NCB-20 neuroblastoma cells and rat cerebral cortex using [3H]-quipazine and [3H]-GR65630 binding.
Sharif NA; Wong EH; Loury DN; Stefanich E; Michel AD; Eglen RM; Whiting RL
Br J Pharmacol; 1991 Apr; 102(4):919-25. PubMed ID: 1830236
[TBL] [Abstract][Full Text] [Related]
17. Allosteric modulation of 5-HT(1A) receptors by zinc: Binding studies.
Barrondo S; Sallés J
Neuropharmacology; 2009 Feb; 56(2):455-62. PubMed ID: 18951909
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor.
Wainscott DB; Cohen ML; Schenck KW; Audia JE; Nissen JS; Baez M; Kursar JD; Lucaites VL; Nelson DL
Mol Pharmacol; 1993 Mar; 43(3):419-26. PubMed ID: 8450835
[TBL] [Abstract][Full Text] [Related]
19. Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide.
Choi SK; Green D; Ho A; Klein U; Marquess D; Taylor R; Turner SD
J Med Chem; 2008 Jun; 51(12):3609-16. PubMed ID: 18507369
[TBL] [Abstract][Full Text] [Related]
20. Mapping of serotonin 5-HT(4) receptor mRNA and ligand binding sites in the post-mortem human brain.
Bonaventure P; Hall H; Gommeren W; Cras P; Langlois X; Jurzak M; Leysen JE
Synapse; 2000 Apr; 36(1):35-46. PubMed ID: 10700024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
